{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:46:02Z","timestamp":1787165162442,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH_E_113287"],"award-info":[{"award-number":["TSGH_E_113287"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07643-4","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T02:33:45Z","timestamp":1734057225000},"page":"1321-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association Between Clinical Use of Lansoprazole and the Risk of Coronary Heart Disease: A Nationwide Pharmacoepidemiological Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Ming-Hsun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Kun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Shun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-0537","authenticated-orcid":false,"given":"Chien-An","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"4","key":"7643_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","volume":"14","author":"N El Rouby","year":"2018","unstructured":"El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447\u201360.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"7643_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut and liver. 2017;11(1):27.","journal-title":"Gut and liver"},{"issue":"3","key":"7643_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/10408444.2019.1583167","volume":"49","author":"N Farhat","year":"2019","unstructured":"Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49(3):215\u201361.","journal-title":"Crit Rev Toxicol"},{"issue":"8","key":"7643_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","volume":"128","author":"YT Ghebremariam","year":"2013","unstructured":"Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845\u201353.","journal-title":"Circulation"},{"key":"7643_CR5","doi-asserted-by":"crossref","unstructured":"Bell EJ, Bielinski SJ, Sauver JLS et al., editors. Association of proton pump inhibitors with higher risk of cardiovascular disease and heart failure. Mayo Clinic Proceedings; 2021: Elsevier.","DOI":"10.1016\/j.mayocp.2021.02.025"},{"key":"7643_CR6","doi-asserted-by":"crossref","unstructured":"Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. American College of Cardiology Foundation Washington, DC; 2019. p. 2529\u201332.","DOI":"10.1016\/j.jacc.2019.10.009"},{"issue":"9438","key":"7643_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"issue":"9","key":"7643_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135\u201343.","journal-title":"Circulation"},{"issue":"7","key":"7643_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1172\/JCI29024","volume":"116","author":"CF Semenkovich","year":"2006","unstructured":"Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Investig. 2006;116(7):1813\u201322.","journal-title":"J Clin Investig"},{"issue":"1","key":"7643_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1124\/jpet.109.152702","volume":"331","author":"T Takagi","year":"2009","unstructured":"Takagi T, Naito Y, Okada H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther. 2009;331(1):255\u201364.","journal-title":"J Pharmacol Exp Ther"},{"key":"7643_CR11","doi-asserted-by":"publisher","first-page":"116897","DOI":"10.1016\/j.lfs.2019.116897","volume":"239","author":"A Benchamana","year":"2019","unstructured":"Benchamana A, Mori H, MacDougald OA, Soodvilai S. Regulation of adipocyte differentiation and metabolism by lansoprazole. Life Sci. 2019;239:116897.","journal-title":"Life Sci"},{"issue":"1","key":"7643_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41591-020-1126-7","volume":"27","author":"T Becher","year":"2021","unstructured":"Becher T, Palanisamy S, Kramer DJ, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27(1):58\u201365.","journal-title":"Nat Med"},{"key":"7643_CR13","doi-asserted-by":"publisher","first-page":"652246","DOI":"10.3389\/fendo.2021.652246","volume":"12","author":"H-J Chen","year":"2021","unstructured":"Chen H-J, Meng T, Gao P-J, Ruan C-C. The role of brown adipose tissue dysfunction in the development of cardiovascular disease. Front Endocrinol. 2021;12:652246.","journal-title":"Front Endocrinol"},{"issue":"3","key":"7643_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","volume":"101","author":"V Pasceri","year":"2000","unstructured":"Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator\u2013activated receptor-\u03b3 activators. Circulation. 2000;101(3):235\u20138.","journal-title":"Circulation"},{"key":"7643_CR15","doi-asserted-by":"crossref","unstructured":"Hsieh C-Y, Su C-C, Shao S-C et al. Taiwan\u2019s national health insurance research database: past and future. Clin Epidemiol. 2019;11:349\u201358.","DOI":"10.2147\/CLEP.S196293"},{"key":"7643_CR16","doi-asserted-by":"publisher","unstructured":"Cheng C-L, Kao Y-HY, Lin S-J, Lee C-H, Lai ML. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Safety. 2011;20(3):236\u201342. https:\/\/doi.org\/10.1002\/pds.2087.","DOI":"10.1002\/pds.2087"},{"issue":"1","key":"7643_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/pds.1324","volume":"16","author":"CS Gau","year":"2007","unstructured":"Gau CS, Chang IS, Lin Wu FL, et al. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidemiol Drug Saf. 2007;16(1):86\u201395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"18","key":"7643_CR18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"C-Y Wu","year":"2012","unstructured":"Wu C-Y, Chen Y-J, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906\u201313.","journal-title":"JAMA"},{"issue":"2","key":"7643_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/nu11020463","volume":"11","author":"A Worthmann","year":"2019","unstructured":"Worthmann A, Schlein C, Berb\u00e9e JF, et al. Effects of pharmacological thermogenic adipocyte activation on metabolism and atherosclerotic plaque regression. Nutrients. 2019;11(2):463.","journal-title":"Nutrients"},{"key":"7643_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2019.02.007","volume":"283","author":"J-J Yeh","year":"2019","unstructured":"Yeh J-J, Lin C-L, Hsu CY, Shae Z, Kao C-H. Associations between statins and coronary artery disease and stroke risks in patients with asthma\u2013chronic obstructive pulmonary disease overlap syndrome: a time-dependent regression study. Atherosclerosis. 2019;283:61\u20138.","journal-title":"Atherosclerosis"},{"issue":"6","key":"7643_CR21","first-page":"634","volume":"35","author":"K-H Huang","year":"2019","unstructured":"Huang K-H, Tai C-J, Tsai Y-F, Kuan Y-H, Lee C-Y. Correlation between gout and coronary heart disease in Taiwan: a nationwide population-based cohort study. Acta Cardiologica Sinica. 2019;35(6):634.","journal-title":"Acta Cardiologica Sinica"},{"issue":"18","key":"7643_CR22","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/heartjnl-2014-305652","volume":"100","author":"L-C Hsiao","year":"2014","unstructured":"Hsiao L-C, Muo C-H, Chen Y-C, et al. Increased risk of coronary heart disease in patients with chronic osteomyelitis: a population-based study in a cohort of 23 million. Heart. 2014;100(18):1450\u20134.","journal-title":"Heart"},{"issue":"2","key":"7643_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/biomet\/74.2.289","volume":"74","author":"R Gill","year":"1987","unstructured":"Gill R, Schumacher M. A simple test of the proportional hazards assumption. Biometrika. 1987;74(2):289\u2013300.","journal-title":"Biometrika"},{"issue":"4","key":"7643_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","volume":"27","author":"TP Shiraev","year":"2018","unstructured":"Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443\u201350.","journal-title":"Heart Lung Circ"},{"issue":"8","key":"7643_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/circulationaha.113.003602","volume":"128","author":"YT Ghebremariam","year":"2013","unstructured":"Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845\u201353. https:\/\/doi.org\/10.1161\/circulationaha.113.003602.","journal-title":"Circulation"},{"key":"7643_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","volume":"64","author":"S Shi","year":"2008","unstructured":"Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935\u201351.","journal-title":"Eur J Clin Pharmacol"},{"key":"7643_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","volume":"23","author":"G Sachs","year":"2006","unstructured":"Sachs G, Shin J, Howden C. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23:2\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"7643_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bbrc.2014.04.127","volume":"448","author":"S Zhang","year":"2014","unstructured":"Zhang S, Wang Y, Li SJ. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochem Biophys Res Commun. 2014;448(4):424\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"7643_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bcp.2018.05.005","volume":"154","author":"J Nantavishit","year":"2018","unstructured":"Nantavishit J, Chatsudthipong V, Soodvilai S. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion. Biochem Pharmacol. 2018;154:175\u201382.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"7643_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1507\/endocrj.EJ14-0208","volume":"61","author":"K Takebayashi","year":"2014","unstructured":"Takebayashi K, Sakurai S, Suzuki T, et al. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocr J. 2014;61(10):1031\u20139.","journal-title":"Endocr J"},{"issue":"8","key":"7643_CR31","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-009-1390-z","volume":"52","author":"W Suarez-Pinzon","year":"2009","unstructured":"Suarez-Pinzon W, Cembrowski G, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009;52(8):1680\u20132.","journal-title":"Diabetologia"},{"key":"7643_CR32","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1007\/s00125-010-1825-6","volume":"53","author":"T B\u00f6dvarsd\u00f3ttir","year":"2010","unstructured":"B\u00f6dvarsd\u00f3ttir T, Hove K, Gotfredsen C, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia. 2010;53:2220\u20133.","journal-title":"Diabetologia"},{"issue":"7","key":"7643_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","volume":"23","author":"W Wahli","year":"2012","unstructured":"Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23(7):351\u201363.","journal-title":"Trends Endocrinol Metab"},{"key":"7643_CR34","doi-asserted-by":"crossref","unstructured":"Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta (BBA)-Lipids Lipid Metab. 1996;1302(2):93\u2013109.","DOI":"10.1016\/0005-2760(96)00066-5"},{"issue":"6","key":"7643_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2174\/1381612822666161006151134","volume":"23","author":"D Nikolic","year":"2017","unstructured":"Nikolic D, Castellino G, Banach M, et al. PPAR agonists, atherogenic dyslipidemia and cardiovascular risk. Curr Pharm Des. 2017;23(6):894\u2013902.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"7643_CR36","first-page":"60","volume":"1","author":"L Badimon","year":"2012","unstructured":"Badimon L, Padr\u00f3 T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2012;1(1):60\u201374.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"11","key":"7643_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jacc.2012.02.082","volume":"60","author":"M Marzilli","year":"2012","unstructured":"Marzilli M, Merz CNB, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012;60(11):951\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7643_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1042\/CS20190577","volume":"134","author":"S Ahmadieh","year":"2020","unstructured":"Ahmadieh S, Kim HW, Weintraub NL. Potential role of perivascular adipose tissue in modulating atherosclerosis. Clin Sci. 2020;134(1):3\u201313.","journal-title":"Clin Sci"},{"issue":"22","key":"7643_CR39","doi-asserted-by":"publisher","first-page":"e021003","DOI":"10.1161\/JAHA.121.021003","volume":"10","author":"T McLaughlin","year":"2021","unstructured":"McLaughlin T, Schnittger I, Nagy A, et al. Relationship between coronary atheroma, epicardial adipose tissue inflammation, and adipocyte differentiation across the human myocardial bridge. J Am Heart Assoc. 2021;10(22):e021003.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"7643_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/metabo11050319","volume":"11","author":"CL Roth","year":"2021","unstructured":"Roth CL, Molica F, Kwak BR. Browning of white adipose tissue as a therapeutic tool in the fight against atherosclerosis. Metabolites. 2021;11(5):319.","journal-title":"Metabolites"},{"issue":"1","key":"7643_CR41","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1038\/ncomms7356","volume":"6","author":"JF Berb\u00e9e","year":"2015","unstructured":"Berb\u00e9e JF, Boon MR, Khedoe PPS, et al. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun. 2015;6(1):6356.","journal-title":"Nat Commun"},{"issue":"5","key":"7643_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmet.2013.04.001","volume":"17","author":"PR Nagareddy","year":"2013","unstructured":"Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17(5):695\u2013708.","journal-title":"Cell Metab"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07643-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:52Z","timestamp":1766127652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7643"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07643-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Institutional Review Board of Fu-Jen Catholic University (FJU-IRB No: C104014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Since the dataset was released for research purposes and contained only de-identified information on patient identification, informed consent from the patients was deemed exempt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no commercial associations or sources of support that might pose a conflict of interest. All authors have made substantive contributions to the study, and all authors endorse the data and conclusions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}